Overview

The Medicine Innovation Program

Throughout the Department of Medicine, talented faculty are developing innovative, cost-effective technologies that have the potential to significantly impact patient care. The Medicine Innovation Program (MIP) was launched in 2015 to support and advance these innovations. Over the past four years, MIP has provided seed funding to a diverse portfolio of projects in the artificial intelligence and digital health spaces, as well as to the development of novel therapeutics and medical devices. In 2017, MIP launched the ROCK STARt-up Associate Program with Third Rock Ventures, a leading biotechnology venture firm in Boston. This program gives faculty, interested in entrepreneurship, the opportunity to build successful and translational scientific ventures from the ground up. MIP is led by Christiana Iyasere MD, MBA.

Our Team

Christiana Iyesere, MD, MBA is the director of the Medicine Innovation Program. She is an established leader in developing innovative platforms focused on improving patient care. A graduate of Yale University, Columbia University College of Physicians and Surgeons, and Harvard University Business School, Christiana served as a Howard Hughes Research Fellow in HIV Immunology for the Laboratory of Immunoregulation at the National Institutes of Health. She completed her Internal Medicine Residency at Massachusetts General Hospital and served for a year as an Administrative Fellow alongside Dr. Peter Slavin, leading a series of projects related to optimal technology adoption and utilization. She has served in prominent roles such as Co-Director of the MGH Innovation Support Center; Associate Director of “The Sandbox,” a clinical innovation site; Technology Assessment Coordinator for the Council for Technology, Adoption, Innovation, and Promotion; and Chair of the Mass General Innovation Collaborative. She is a member of the Partners Innovation Council and the Partners Epic Innovation Council. Christiana is also an Assistant Professor of Medicine at Harvard Medical School.


Gabrielle Geonnotti, MPH, is the Program Administrator for the Medicine Innovation Program. She assists with the coordination of the annual RFP and helps support MIP awardees throughout the duration of their grants. Gabrielle graduated from The George Washington University and holds a Master of Public Health degree from The University of Edinburgh. Her masters dissertation focused on priority setting in global child health, shaping her interest in investing in innovative research and technologies. Before joining the Department of Medicine at MGH, she worked in the pharmaceutical industry, recruiting sales teams and later building digital platforms for nurses treating patients with autoimmune diseases.

Advisory Board

MIP Advisory Board

Mark Poznansky, MD, PhD Director of the Vaccine and Immunotherapy Center

Kristian Olson, MD, Director, CAMTech

Emy Chan, PhD, Director, Partners HealthCare Innovation

Jeffrey Gelfand, MD, 2015 MIP Awardee

Shaw Warren, MD, Associate Faculty Wyss Institute at Harvard University,

Martha Gray, PhD, Director, Madrid-MIT m+vision consortium

Petra Krauledat, PhD, Principal, PNPResearch Corporation

Peter Hansen, PhD, Principal, PNPResearch Corporation

Larry Miller, MD, MPH, President, Apnimed, Inc.

Eric Isselbacher, MD, Director, Healthcare Transformation Lab

Joshua Metlay, MD, PhD, Chief of the Division of General Internal Medicine

Thomas McCoy, MD, 2017 MIP Awardee

Our Programs

Medicine Innovation Pilot Grant Awards

The Medicine Innovation Pilot Grant Awards take research projects with the potential to transform medicine and provides them with the needed resources to move forward to the next inflection point in successful solution development. Resources provided include structured project management support, milestone based stewardship of resources, focused mentorship and access to networks that can move the project to the next step in development. The goal is to move from a project to a product that can be consumed and used by patients and providers.

MIP actively supports projects for one year to 18 months depending on the needs of the project and project team. Many of MIP’s projects have gone on to attain follow-on grant funding, industry partnerships, or successful adoption into the existing healthcare infrastructure.

ROCK STARt-up Associate Program

The ROCK STARt-Up Associate Program is a 2-year associate program in which MGH DOM faculty will be immersed in the biotech start-up environment at Third Rock Ventures (TRV) in Boston, MA. The Boston Biotech community is one of the most robust in the world and TRV is one of the leading venture capital groups in the country. Consequently, the potential for MGH DOM faculty to actively participate in and build translational opportunities is unparalleled.

TRV has a unique translational model: the group builds companies from the ground up, starting in an area defined by clinical need and scientific opportunity. As a result, they represent an entrepreneurial environment in which MGH DOM faculty can participate in the process of building a successful scientific venture from its early beginnings.

For more information on the Associate experience at 3rd Rock, please visit: 

http://www.thirdrockventures.com/

Program Goals:

  • Experience/exposure of MGH faculty to the translational, entrepreneurial environment of early biotech start-ups and company creation
  • Faculty career development: scientific idea translation, concept de-risking, company formation*
  • Broadening of the translational expertise of the MGH Department of Medicine
  • The associate will participate in the entrepreneurial environment at 3rd Rock
  • The program does not include the development of personal ideas or inventions from participants lab and/or experience at MGH

 

 

For more information please contact:

Christiana Iyasere, MD, MBA

Director, MGH DOM Medicine Innovation Program (MIP), Rock Star Associate program

 

 

 

Portfolio

Digital Health

  • Allergy Passport
    Digital Application for documentation of food allergies
    Kimberley Blumenthal, MD
    2016 Awardee

  • DreAMLand
    Digital Application for support of patients with Acute Myeloid Leukemia 
    Areej El-Jawahri, MD
    2017 Awardee

Artificial Intelligence

  • PROE PCI
    Risk assessment for patient and physician prior to cardiac catheterization for improved decision making
    Jason Wasfy, MD, MPH
    2015 Awardee

  • Clinical Data Visualization and Machine Learning  
    Deep learning to extract useful information for clinical decision making
    Tom McCoy, MD
    2017 Awardee

  • Natural Language Processing in the Evaluation and Diagnosis of Irritable Bowel Syndrome
    Kyle Staller, MD, MPH
    2018 Awardee

Therapeutics and Medical Devices

  • Long Acting Parathyroid Hormone
    First in class drug for treatment of Hypoparathyroidism
    Michael Mannstadt, MD, PhD
    2015 Awardee

  • Laser Therapy for Treatment of Resistant Urinary Tract Infections
    Novel treatment of urinary tract infections with light based therapy
    Jeffery Gelfand, MD
    2015 Awardee

  • Allergy Tolerance
    Laser therapy to induce immune tolerance to food allergens
    Satoshi Kashiwagi, MD, PhD
    2016 Awardee

  • Day Zero Diagnostics
    Diagnosis of bacterial species and sensitivities within hours
    Douglas Kwon, MD, PhD
    2016 Awardee

  • Novel Osteoporosis Therapy
    New oral therapy for osteoperosis
    Mark Wein, MD, PhD
    2017 Awardee

Our Partners

Contact Us

Medicine Innovation Program (MIP)

Massachusetts General Hospital
55 Fruit Street
Gray Building, 7-730
Boston, MA 02114
E-mail us

Back to Top